Nasus Pharma Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Nasus Pharma Ltd., a foreign private issuer based in Tel Aviv, Israel, was submitted on September 4, 2026. The report discloses the convening of an Annual and Special General Meeting of Shareholders scheduled for October 8, 2026. The record date for shareholders entitled to vote is set for September 14, 2026.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a notice of a shareholder meeting and incorporates proxy materials by reference rather than presenting a financial results report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this specific filing text. The primary disclosure is the procedural announcement of the upcoming shareholder meeting.
Guidance, Outlook, and Risks
Management commentary, financial guidance, outlook, risks, contingencies, and unusual items are not detailed in the body of this Form 6-K. These details are expected to be contained within the attached Proxy Statement (Exhibit 99.2), which is incorporated by reference.
Key Facts for Investor Verification
- Meeting Date: October 8, 2026.
- Record Date: September 14, 2026 (shareholders must hold ordinary shares by this date to vote).
- Meeting Type: Annual and Special General Meeting of Shareholders.
- Exhibits: Notice of Meeting (99.1), Proxy Statement (99.2), and Proxy Card (99.3) are attached and incorporated.
- Registration Statements: This report is incorporated by reference into Form F-3 (File No. 333-298693) and Form S-8 (File No. 333-296252).